BreathPass
A proprietary handheld electronic nose for capturing breath signatures in clinical, field, and research settings.
Electronic nose platform
Non-invasive breath analysis for diagnosis, prediction, and discovery.
Digital Sensing Technologies develops and deploys a complete e-Nose platform that transforms exhaled breath into actionable medical and research insights. Our technology enables non-invasive diagnosis, disease phenotyping, and predictive analytics across medical and scientific domains.
VOCs
Volatile organic compounds reflect metabolic and physiological processes in real time.
BreathPass
A proprietary handheld electronic nose for clinical and research use.
Cloud + AI
Secure study infrastructure with analytical models for classification and prediction.
Why breath?
Breath contains molecular information the body releases continuously.
Breath contains thousands of volatile organic compounds that reflect metabolic and physiological processes in real time.
Changes in human odor as indicators of disease have been observed since Hippocrates' time. Only recently has it been scientifically demonstrated that the composition of exhaled breath varies systematically with disease.
Diseased organs excrete different substances into the bloodstream, which are transferred to exhaled air through gas exchange in the lungs. Detecting these changes, and how they evolve over time, is crucial.
Electronic noses make it possible to detect and interpret these complex VOC patterns in a scalable and non-invasive way.
What we do
An end-to-end breath-analysis platform.
Together, these components allow complex breath signatures to be captured, stored, and analyzed at scale.
DST Cloud
Secure storage and study infrastructure for multi-site breath research and compliant data handling.
Analytical algorithms
Classification, phenotyping, and prediction models designed to translate VOC patterns into usable signals.
Medical applications
Non-invasive breath analysis for neurological insight.
Digital Sensing Technologies is advancing breath analysis as a medical diagnostic and predictive tool, with a current focus on epilepsy.
The unmet need in epilepsy
Epilepsy is one of the most common neurological conditions, affecting over 50 million people worldwide. Diagnosis remains challenging, and over 30% of patients cannot achieve seizure control with medication.
These patients live in daily uncertainty, not knowing whether a seizure will occur that day. This uncertainty is a major source of stress and a limiting factor socially, professionally, and economically.
What if we could predict whether a seizure is likely to happen, or not?
Diagnosis support
We investigate whether breath profiles can distinguish epilepsy patients from healthy or non-epileptic controls, supporting faster and less burdensome diagnostic pathways.
Seizure prediction
We study whether measurable changes in breath composition occur before or shortly after seizures, aiming to enable early warnings, improved safety, and better disease management.
Scientific proof
Seizures have a smell.
Scientific studies have shown that trained dogs can reliably detect odor associated with epileptic seizures in humans. Dogs spent significantly more time exploring odor samples taken around seizures than samples from physical exercise or calm activity.
These findings support the hypothesis that seizures may be anticipated based on changes in body odor or breath, using electronic solutions such as e-Noses.
Clinical experience
The BreathPass platform has been used in multiple countries in clinical environments, including deployments for COVID-19 diagnosis and screening. This experience informs usability, workflows, data quality, and repeatability.
Development approach
Observational and interventional studies, secure data handling, alignment with medical device regulations, and stepwise claim development from diagnosis to prediction.
Clinical partners
We collaborate with hospitals, epilepsy centers, academic medical centers, and clinical research organizations interested in validation studies.
Research and innovation
A flexible breath-analysis platform for discovery and development.
Beyond regulated medical applications, DST offers its platform to research organizations and innovation partners seeking novel insights from breath data.
Our technology is application-agnostic and well suited for exploratory, translational, and pre-commercial research.
- Immediate access to a validated e-Nose system
- Secure cloud and data infrastructure
- Proven analytical framework
- Speed from hypothesis to data
- Flexibility from research to commercialization
What you can do
Perform breath-based biomarker discovery, study disease phenotypes or metabolic states, run longitudinal or multi-site studies, and explore AI-driven pattern recognition on VOC data.
Engagement models
Platform leasing for research use, technology licensing for product integration, and co-development for validation, regulatory, and market pathways.
Who we work with
Academic and applied research institutes, pharma and biotech R&D teams, medtech innovators, diagnostics companies, and public or private research organizations.
Intellectual property
Protecting the core platform and high-impact applications.
Digital Sensing Technologies is building a proprietary breath-analysis platform combining advanced sensor technology, AI-driven pattern recognition, and validated breath sampling to detect and predict physiological conditions through exhaled air.
The company is actively developing an intellectual property portfolio around both the core platform technology and specific high-impact applications.
Forensic detection applications
NewLife Wearables has filed patent applications relating to the use of breath analysis for rapid, non-invasive forensic screening in operational environments such as border control, customs, detention facilities, and law-enforcement screening.
Rather than attempting to directly detect concealed substances, the platform analyses physiological VOC-response patterns present in exhaled breath.
Patent applications cover
- Breath-analysis hardware
- Controlled sampling environments
- VOC sensor systems
- Environmental compensation
- Breath validation
- AI-supported classification methods
The goal is to enable fast, scalable, and non-invasive pre-screening workflows suitable for high-throughput operational use.
Breath analysis platform technology
In parallel, NewLife Wearables is pursuing broader patent protection around its generic breath-analysis platform.
The platform is designed to support detection and prediction of physiological and psychophysiological states using VOC sensing, environmental sensing, validated breath sampling, and AI-based analysis.
Future application areas include
- Neurological conditions
- Predictive health monitoring
- Infection and inflammation monitoring
- Stress and fatigue analysis
- Wellness applications
- Other breath-based diagnostic workflows
Portfolio protection includes
- Sensor architectures
- Climate-controlled sensing environments
- Multi-sensor signal analysis
- Breath-quality validation
- AI-supported classification systems
Research and data platform
The platform is designed as a continuously improving research ecosystem that combines handheld breath-analysis hardware, AI-supported analytics, cloud-connected infrastructure, and longitudinal data collection.
It supports biomarker discovery research and future deployment in clinical, forensic, and wellness environments. Current research includes epilepsy and seizure prediction, where the platform aims to identify breath patterns associated with increased seizure likelihood before a seizure occurs.
Long-term vision
DST aims to build a scalable breath-analysis platform that can support multiple applications from a shared technological foundation.
The intellectual property strategy is intended to protect the core sensing platform, the AI-driven interpretation methods, and future application domains built on top of the technology.
About us
Technology depth with a mission-driven clinical focus.
Digital Sensing Technologies combines the BreathPass technology base of Deep Sensing Algorithms with the epilepsy-focused mission and clinical network of NewLife Wearables.
2020
Deep Sensing Algorithms founded
DSA was founded in Finland to create fast and reliable COVID tests with immediate results at large scale, building a technology-driven e-Nose platform with clinical experience.
Mission
NewLife Wearables focus
NewLife Wearables was founded to explore whether epileptic seizures can be predicted through changes in exhaled breath.
2024
Platform unification
NewLife Wearables acquired DSA, unifying proven technology, clinical track record, mission-driven vision, team, and funding.
Today
Digital Sensing Technologies
DST brings together medical technology, sensor systems, data science, AI, clinical research, strategy, and scale-up expertise.
Ecosystem and partners
Tampere
Rennes
SEIN
Kempenhaeghe
Dutch Customs
Technology partners
Call to action
Interested in medical collaboration or research access?
Contact us to explore studies, partnerships, platform leasing, technology licensing, or co-development.
info@digitalsensing.tech